Opin vísindi

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls


Title: Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
Author: Shah, Urvi A.
Rögnvaldsson, Sæmundur
Derkach, Andriy
Björkholm, Magnus
Turesson, Ingemar
David, Yael
Hultcrantz, Malin
Tan, Carlyn
Hassoun, Hani
Korde, Neha
... 4 more authors Show all authors
Date: 2022-01-01
Language: English
Scope: 3
Department: Internal Medicine and Emergency Services
Faculty of Medicine
Cancer Center
Series: Haematologica; 107(1)
ISSN: 0390-6078
DOI: https://doi.org/10.3324/haematol.2021.278772
Subject: Diabetes Mellitus; Humans; Lymphoproliferative Disorders/diagnosis; Plasma Cells; Sykursýki
URI: https://hdl.handle.net/20.500.11815/3333

Show full item record

Citation:

Shah , U A , Rögnvaldsson , S , Derkach , A , Björkholm , M , Turesson , I , David , Y , Hultcrantz , M , Tan , C , Hassoun , H , Korde , N , Lesokhin , A , Mailankody , S , Kristinsson , S Y & Ola Landgren , C 2022 , ' Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls ' , Haematologica , vol. 107 , no. 1 , pp. 284-286 . https://doi.org/10.3324/haematol.2021.278772

Description:

Funding Information: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 (UAS) and supported by grants from Swedish Cancer Society (MB), Parker Institute of Cancer Immunotherapy Career Development Award (YD, UAS), International Myeloma Society Career Development Award, Paula and Rodger Riney Foundation, American Society of Hematology Clinical Research Training Institute Award and TREC Training Workshop R25CA203650 (PI: Melinda Irwin) (UAS). Funding Information: Contributions: all authors participated in the writing and review of the manuscript. Additionally UAS and SR designed the study and performed data analysis; AD performed data analysis and designed statistical methods; MB and IT curated the data and were involved in study design conception; YD, SP, MH, CT, HH, NK, AL, and SM were involved in study design conception; SYK and COL curated the data, designed the study, and supervised the research project. Acknowledgments: the authors would like to thank Hannah Rice, BA, ELS for editorial assistance. Funding: this research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 (UAS) and supported by grants from Swedish Cancer Society (MB), Parker Institute of Cancer Immunotherapy Career Development Award (YD, UAS), International Myeloma Society Career Development Award, Paula and Rodger Riney Foundation, American Society of Hematology Clinical Research Training Institute Award and TREC Training Workshop R25CA203650 (PI: Melinda Irwin) (UAS). Data sharing statement: The data included in study is built on multiple population-based registries including the medical records of Swedish citizens. Although the data has been made unidentifiable before analysis, ethical board approval does not permit data sharing.

Files in this item

This item appears in the following Collection(s)